Lepu Biopharma Co. Ltd. Class H (2157) AI Stock Analysis

• Market Cap: HK$9.10B
• Dividend Yield: N/A
• Average Volume (3M): 20.07M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: 58.75%
• EPS Growth: -1310.16%
• Country: HK
• Employees: 498
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 1,656,346,400
• 10 Day Avg. Volume: 32,841,579
• 30 Day Avg. Volume: 20,070,842
• PEG Ratio: 0.50
• Price to Book (P/B): 11.82
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -18.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ―

The overall stock score for Lepu Biopharma Co. Ltd. reflects significant financial performance challenges, particularly in profitability and cash flow management, which weigh heavily on the score. The technical analysis indicates strong positive momentum, which boosts the score, but the negative valuation due to ongoing losses remains a concern. Without earnings call data or notable corporate events, these elements do not affect the score.

Lepu Biopharma Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Lepu Biopharma Co. Ltd. Class H (2157) is a Chinese biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative pharmaceuticals. The company's primary areas of expertise include oncology, cardiovascular, and other critical therapeutic sectors. Lepu Biopharma is committed to delivering high-quality, cutting-edge healthcare solutions through its robust product pipeline and advanced technological capabilities.

How the Company Makes Money

Lepu Biopharma Co. Ltd. generates revenue through the sale of its pharmaceutical products, particularly focusing on its oncology and cardiovascular drug offerings. The company invests significantly in research and development to create innovative therapies, which are then commercialized and distributed to healthcare providers and institutions. Key revenue streams include direct sales of proprietary drugs, licensing agreements with other pharmaceutical companies, and strategic partnerships that enhance the company's market reach and distribution capabilities. Additional revenue may also be derived from collaborations with academic and research institutions that further the development of new therapeutic solutions.

Lepu Biopharma Co. Ltd. Class H Financial Statement Overview

Summary

Lepu Biopharma Co. Ltd. faces significant challenges in achieving profitability and maintaining financial stability. Despite revenue growth, the company's negative margins and high leverage indicate operational and financial risks. The negative cash flow position further underscores the need for strategic improvements to enhance liquidity and reduce reliance on debt financing.

Income Statement

The company has shown growth in total revenue from 2022 to 2024, with a significant increase in 2024. However, profitability remains a challenge with consistently negative net income, leading to negative net profit margins. The gross profit margin is strong at 79.65% for 2024, but the EBIT and EBITDA margins are negative, pointing to operational inefficiencies.

Balance Sheet

The company's balance sheet reflects a high level of debt with a debt-to-equity ratio of 1.20 in 2024, indicating potential leverage risk. Stockholders' equity has decreased over the years, affecting the equity ratio negatively. The company has sufficient cash reserves, but the decline in equity raises concerns about financial stability.

Cash Flow

Cash flow from operations is consistently negative, and free cash flow has also remained negative, reflecting challenges in generating cash from core activities. This poses a risk to the company's liquidity position, as it may need to rely on external financing for operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
367.79M	225.35M	15.57M	0.00	0.00
	Gross Profit
292.97M	197.07M	13.57M	0.00	0.00
	EBIT
-390.76M	4.80M	-704.48M	-1.01B	-520.35M
	EBITDA
-311.94M	86.95M	-596.53M	-865.23M	-371.01M
	Net Income Common Stockholders
-411.38M	-22.10M	-689.05M	-1.01B	-581.85M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
464.91M	498.43M	669.40M	205.17M	753.52M
	Total Assets
2.28B	2.38B	2.53B	2.08B	2.42B
	Total Debt
850.16M	746.82M	690.30M	335.26M	203.08M
	Net Debt
448.88M	320.81M	20.91M	180.09M	-199.79M
	Total Liabilities
1.60B	1.50B	1.63B	1.23B	921.89M
	Stockholders Equity
702.83M	896.90M	900.76M	836.71M	1.47B
Cash Flow		Free Cash Flow
0.00	-292.04M	-591.38M	-835.12M	-724.51M
	Operating Cash Flow
0.00	-250.84M	-480.93M	-621.74M	-422.69M
	Investing Cash Flow
0.00	18.26M	-74.66M	-3.89M	-749.67M
	Financing Cash Flow
0.00	-11.01M	1.03B	380.31M	1.39B

Lepu Biopharma Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2157, the sentiment is Positive. The current price of 5.82 is above the 20-day moving average (MA) of 5.14, above the 50-day MA of 4.64, and above the 200-day MA of 3.44, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 62.31 is Neutral, neither overbought nor oversold. The STOCH value of 43.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2157.

Lepu Biopharma Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2359	78 Outperform	HK$201.01B	17.72	21.68%	75.12%	-0.45%	6.17%
1093	76 Outperform	$87.51B	19.03	13.20%	2.63%	-9.60%	-27.18%
2269	74 Outperform	HK$98.06B	27.18	8.17%	―	7.52%	-1.92%
9926	55 Neutral	HK$82.62B	―	-8.98%	―	-54.66%	-123.11%
Sector *	53 Neutral	$5.22B	3.33	-44.36%	7.55%	16.78%	-0.12%
1877	52 Neutral	HK$32.88B	―	-19.78%	―	25.96%	39.58%
2157	45 Neutral	HK$9.10B	―	-51.40%	―	58.75%	-1310.16%

Lepu Biopharma Co. Ltd. Class H Corporate Events

Lepu Biopharma’s MRG003 Gains Recognition at 2025 ASCO Annual Meeting

Lepu Biopharma Co., Ltd. announced that its Phase IIb study results for MRG003, an innovative ADC targeting EGFR for recurrent or metastatic nasopharyngeal cancer, have been selected for oral presentation at the 2025 ASCO Annual Meeting. This recognition highlights the potential impact of MRG003 in cancer treatment, although the company cautions that successful development and marketing are not guaranteed, advising shareholders and investors to exercise caution.

Lepu Biopharma Reports Strong Revenue Growth and Pipeline Advancements in 2024

Lepu Biopharma Co., Ltd. reported a significant increase in revenue for the year ending December 31, 2024, driven by the commercialization of its Pucotenlimab Injection and licensing income from its CMG901 product. The company also made notable advancements in its ADC pipeline, with several products entering advanced stages of clinical trials and receiving regulatory approvals, which could enhance its market positioning and offer promising treatment options for cancer patients.

Lepu Biopharma Schedules Board Meeting to Review Annual Results

Lepu Biopharma Co., Ltd. has announced that its Board of Directors will hold a meeting on March 27, 2025, to consider and approve the company’s annual results for the year ending December 31, 2024. The meeting will also address the recommendation of a final dividend payment and other business matters. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting its market positioning and stakeholder relations.

Lepu Biopharma Updates NDA Process for Cancer Drug MRG003

Lepu Biopharma Co., Ltd. has announced an update regarding its New Drug Application (NDA) for MRG003, an ADC targeting EGFR for the treatment of recurrent or metastatic nasopharyngeal cancer. The company has voluntarily withdrawn its previous NDA to submit supplementary materials and plans to resubmit the application on March 4, 2025. This move aims to ensure a thorough review process and highlights the company’s commitment to advancing its drug candidate, although it may delay the approval timeline.